Gujarat Magazine

AstraZeneca’s SAPHNELO market size expected to increase many folds by 2032, report DelveInsight

 Breaking News
  • No posts were found

AstraZeneca’s SAPHNELO market size expected to increase many folds by 2032, report DelveInsight

January 23
18:20 2024
AstraZeneca’s SAPHNELO market size expected to increase many folds by 2032, report DelveInsight

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on SAPHNELO (AstraZeneca) providing insights into the drug market landscape and market forecast of SAPHNELO upto 2032. The report, titled “SAPHNELO Market Size, Forecast, and Emerging Insight – 2032” is now available for review and analysis.


Are you interested in finding out the projected market size of SAPHNELO in 2032? Click @ SAPHNELO Market Size


The SAPHNELO Market Report offers projected sales forecasts for SAPHNELO for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.


SAPHNELO Overview:

AstraZeneca’s SAPHNELO is serving as a beacon of hope for the patients suffering from the Lupus Nephritis.

SAPHNELO (anifrolumab), developed by AstraZeneca, is an intravenously administered, fully humanmonoclonal antibody that binds to subunit 1 of the type I IFN receptor, blocking the activity of type IIFN. Type I IFNs, such as IFN-alpha, IFN-beta, and IFN-kappa, are cytokines involved in regulating theinflammatory pathways. Anifrolumab induces rapid internalization of IFNAR1 from the surface ofmonocytes, thereby reducing heterodimerization with IFNAR2 and the setting up of the IFN signalingcomplex. By antagonizing the binding of the different IFNs to the IFNAR1 receptor, anifrolumab blocksSTAT1 phosphorylation and IFN-stimulated response element (ISRE) activity. SAPHNELO is alreadyapproved for the treatment of adult patients with moderate to severe systemic lupus erythematosus(SLE). Saphnelo is approved to treat SLE in more than 60 countries worldwide including the US, EU and Japan,with reviews ongoing in other countries.

The report extensively covers the details and developments related to SAPHNELO, capturing important highlights on developmental pipeline, regulatory status and special designations of SAPHNELO, route of administration, safety and efficacy details.


Do you know your drug’s competitive positioning against SAPHNELO? Download Report: SAPHNELO Market Dynamics


SAPHNELO Market Assessment

This report provides a detailed market assessment of SAPHNELO for Lupus Nephritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.


SAPHNELO Clinical Assessment

The report provides the clinical trials information of SAPHNELO for Lupus Nephritis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

  • SAPHNELO continues to be evaluated in the TULIP-SC Phase III trial assessing subcutaneous deliveryin SLE, and the IRIS Phase III trial in active proliferative lupus nephritis.
  • Additional Phase III trials are planned investigating SAPHNELO in diseases where type I IFN plays akey role, including cutaneous lupus erythematosus, systemic sclerosis and myositis.


SAPHNELO Competitive Landscape 

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the SAPHNELO.


SAPHNELO Market Size in the US

A dedicated section of the report focuses on the expected market size of SAPHNELO for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.


What is a SAPHNELO Prescribed for?

SAPHNELO is prescribed for the treatment of Lupus Nephritis.


Key Highlights of SAPHNELO:

  • The report contains forecasted sales of SAPHNELO for indication till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for Lupus Nephritis.
  • The report also features the qualitative and quantitative analysis with analysts as well as KOL views for SAPHNELO in Lupus Nephritis.


Request for Sample Page @


Why you should buy SAPHNELO Market Report:

  • The report provides future market assessments for SAPHNELO for Lupus Nephritis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
  • Leading SAPHNELO for Lupus Nephritis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAPHNELO 
  • Discover the competitive landscape of SAPHNELO through 7MM
  • Get a Thorough Analysis of the SAPHNELO Development pipeline, Safety & Efficacy of the SAPHNELO, and ROA
  • Thorough SAPHNELO market forecast will help understand how drug is competing with other emerging SAPHNELO
  • Get analysis of the SAPHNELO clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
  • Drug Market forecasts are calculated after taking into consideration KOL viewpoints


Related Reports By DelveInsight:

Lupus Nephritis Market

DelveInsight’s Lupus Nephritis Market Insights, Epidemiology, and Market Forecast 2032’ report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Lupus Nephritis Pipeline

DelveInsight’s, “Lupus Nephritis Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 


About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States